| |
PFS
|
OS
|
|---|
|
Hazard ratio
|
95% CI
|
P
|
Hazard ratio
|
95% CI
|
P
|
|---|
|
CTC
KIN
|
|
CTCBL- to CTC1C-
|
1.00
| | |
1.00
| | |
|
CTCBL+ to CTC1C-
|
1.01
|
0.62–1.64
|
0.981
|
1.68
|
0.85–3.32
|
0.135
|
|
CTCBL+ to CTC1C+
|
2.17
|
1.39–3.37
|
< 0.001
|
5.58
|
3.06–10.15
|
< 0.001
|
|
CTCBL- to CTC1C+
|
2.17
|
0.91–5.14
|
0.079
|
2.56
|
0.76–8.00
|
0.134
|
|
Age at inclusion
|
|
Per year
|
0.99
|
0.98–1.00
|
0.333
|
0.99
|
0.97–1.01
|
0.284
|
|
Number of metastatic sites
|
|
One site
|
1.00
| | |
1.00
| | |
|
Multiple sites
|
0.94
|
0.98–1.01
|
0.832
|
0.59
|
0.24–1.48
|
0.260
|
|
Site of metastasis
|
|
Bone
|
1.00
| | |
1.00
| | |
|
Visceral/local
|
1.10
|
0.59–2.04
|
0.768
|
2.12
|
0.82–5.49
|
0.124
|
|
Both
|
1.27
|
0.68–2.37
|
0.449
|
3.35
|
1.27–8.82
|
0.014
|
|
Line of therapy
|
|
1
|
1.00
| | |
1.00
| | |
|
2
|
1.66
|
1.00–2.75
|
0.049
|
2.01
|
1.02–3.99
|
0.045
|
|
≥ 3
|
2.49
|
1.58–3.94
|
< 0.001
|
2.49
|
1.32–4.65
|
0.004
|
|
Molecular Subtypes
|
|
HR+/HER2-
|
1.00
| | |
1.00
| | |
|
HER2+
|
1.34
|
0.81–2.19
|
0.252
|
1.37
|
0.64–2.91
|
0.418
|
|
TNBC
|
2.58
|
1.53–4.35
|
< 0.001
|
3.92
|
2.11–7.30
|
< 0.001
|
- Bold P values indicate statistical significance.
- HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.
